Idiopathic Triglyceride Deposit Cardiomyovasculopathy Clinical Trial
Official title:
Phase I/IIa Study of CNT-01 in Patients With Idiopathic Triglyceride Deposit
| Verified date | September 2016 |
| Source | Osaka University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Japan: Pharmaceutical and Medical Devices Agency |
| Study type | Interventional |
The purpose of this study is to assess the safety and to examine the index of the efficacy after repeated dosing of CNT-01 in patients with idiopathic triglyceride deposit cardiomyovasculopathy.
| Status | Completed |
| Enrollment | 5 |
| Est. completion date | |
| Est. primary completion date | June 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 20 Years and older |
| Eligibility |
Inclusion Criteria: - Have a definite diagnosis of idiopathic triglyceride deposit cardiomyovasculopathy - After receiving a sufficient explanation upon participation in this study, on a full understanding, patients who obtained the written informed consent from each patient - More than 20 years old at the time of informed consent - Is able to oral intake - Must be willing to comply with protocol-required examination such as BMIPP myocardial scintigraphy Exclusion Criteria: - Have diabetic ketoacidosis - Have a malignancy that is being treated by anticancer drug or anticipated survival is less than three years - Female with pregnant or lactating - Is not able to agree to using intrauterine device, oral contraceptive, condom or having sexual intercourse from the start of taking investigational product to 30 days after the end of the study - Have a New York Heart Association functional classification IV - Have a known history of drug dependence - Is allergic to any component of the investigational product - Is allergic to BMIPP or iodine - Have a known history of clinically significant drug allergy - Have a severe liver dysfunction (Child classification B and C) - Participated in other clinical study within the past 3 months and received an investigational agent including placebo - Being treated with diet containing medium chain fatty acid - Is considered unfit for the study by the Investigator's medical decision |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Japan | Cardiovascular Medicine, Osaka University Hospital | Suita | Osaka |
| Lead Sponsor | Collaborator |
|---|---|
| Osaka University |
Japan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of adverse event | Baseline to Day 29 | Yes | |
| Primary | Change in 12-lead ECG recordings from Baseline | Baseline to Day 29 | Yes | |
| Primary | Change in Blood Pressure from Baseline | Baseline to Day 29 | Yes | |
| Primary | Change in clinical laboratory testings as measured by serum chemistry, hematology and urinalysis from Baseline (composite) | Baseline to Day 29 | Yes | |
| Primary | Change in Body temperature from Baseline | Baseline to Day 29 | Yes | |
| Primary | Change in Pulse rate from Baseline | Baseline to Day 29 | Yes | |
| Secondary | Change in uptake and washout rate in BMIPP myocardial scintigraphy | Baseline to Day 15 | No | |
| Secondary | Change in blood concentration of fatty acid fraction from Baseline (Octanoic acid, Capric acid, Myristic acid, Palmitic acid and Stearic acid) | Baseline to Day 16 | No | |
| Secondary | Change in lipase activity in peripheral polynuclear leucocyte from Baseline | Baseline to Day 29 | No | |
| Secondary | Change in blood lipoprotein fraction from Baseline | Baseline to Day 29 | No | |
| Secondary | Change in vacuolation rate in polynuclear leucocyte from Baseline | Baseline to Day 29 | No | |
| Secondary | Change in frequency in use of nitroglycerin from Baseline | Baseline to Day 29 | No | |
| Secondary | Change in New York Heart Association (NYHA) functional classification from Baseline | Baseline to Day 29 | No | |
| Secondary | Change in reactive hyperemic index from Baseline | Baseline to Day 29 | No | |
| Secondary | Change in score of SF-36 from Baseline | Baseline to Day 29 | No |